| 📌 The essentials On February 27, 2026, the FDA approved YUVIWEL (navepegritide, Ascendis Pharma) under the Accelerated Approval Program for increasing linear growth in children aged 2 years and older with achondroplasia with open epiphyses. This is the first and only once-weekly treatment for achondroplasia and the only approved therapy that provides continuous systemic CNP exposure over the weekly dosing interval. The clinical basis: The Phase 2b APPROACH randomized controlled trial (NCT05598320) published in JAMA Pediatrics (November 2025) showed annualized growth velocity (AGV) of 5.84 cm/year with navepegritide versus 3.88 cm/year with placebo (p less than 0.0001), a difference of nearly 2 cm/year additional growth. Accelerated approval context: continued approval may be contingent on confirmatory trials verifying long-term clinical benefit. AGV is the accepted surrogate endpoint; long-term height and functional outcomes are the subject of ongoing follow-up. How it compares: the only other approved therapy for achondroplasia is vosoritide (Voxzogo, BioMarin), approved in 2021, which requires daily injection. YUVIWEL is weekly. Neither has been compared head-to-head in a clinical trial. Rare Pediatric Disease Priority Review Voucher granted alongside this approval. Commercial availability: expected early Q2 2026. |
|---|
Achondroplasia is the most common form of skeletal dysplasia, affecting approximately 1 in 15,000 to 40,000 live births worldwide. It is caused by a gain-of-function mutation in the FGFR3 gene that overactivates a signaling pathway limiting endochondral bone growth. For decades, treatment was supportive, focused on managing the complications of the condition rather than addressing its underlying biology. That began to change in 2021, when the FDA approved the first drug targeting the root cause of achondroplasia. On February 27, 2026, a second drug entered clinical use offering the same mechanistic approach with a meaningful practical difference: once-weekly dosing instead of once-daily.
YUVIWEL (navepegritide) was developed by Ascendis Pharma using their TransCon technology. Its FDA approval under the Accelerated Approval Program makes it the first and only once-weekly treatment for achondroplasia, supported by robust Phase 2b trial data published in JAMA Pediatrics and presented at major pediatric endocrinology meetings.
What Achondroplasia Is and Why It Extends Beyond Height
To understand what navepegritide does, it helps to understand what achondroplasia actually is, because the condition is more than a difference in stature.
Achondroplasia causes characteristic skeletal features including short stature with rhizomelic (proximal limb) shortening, enlarged head circumference with midface hypoplasia, exaggerated lumbar lordosis, and bowed legs. The average adult height in achondroplasia is approximately 4 feet 1 inch (125 cm) in women and 4 feet 4 inches (131 cm) in men. But height is one dimension of the condition’s impact.
Achondroplasia is a multisystem condition. Many affected individuals face:
- Spinal cord compression at the foramen magnum, which can cause central apnea and is the leading cause of sudden death in infancy in achondroplasia
- Spinal stenosis in adulthood, causing pain, weakness, and neurological symptoms
- Obstructive sleep apnea, occurring in a majority of affected children
- Recurrent otitis media and associated hearing loss due to midface hypoplasia
- Varus deformity (bowing) of the lower extremities affecting mobility and joint health
This multisystem burden is why the pediatric orthopedic and skeletal dysplasia research community frames achondroplasia pharmacotherapy in terms of improving overall skeletal development, not simply maximizing height. The APPROACH trial endpoints reflect this: in addition to AGV, the trial measured tibial-femoral angle, mechanical axis deviation, fibula-to-tibia length ratio, and the Achondroplasia Child Experience Measure for physical functioning.
The Mechanism: CNP and the FGFR3 Pathway
The biology behind navepegritide requires understanding what the FGFR3 mutation actually does and how CNP counteracts it.
In normal bone growth, endochondral ossification converts cartilage to bone at growth plates. This process depends on chondrocyte (cartilage cell) proliferation and differentiation being maintained at the appropriate rate. FGFR3 (fibroblast growth factor receptor 3) normally acts as a brake on this process. In achondroplasia, the gain-of-function FGFR3 mutation overactivates this brake through the MAPK signaling pathway, suppressing chondrocyte proliferation and slowing bone elongation.
C-type natriuretic peptide (CNP) is a naturally occurring peptide that counteracts FGFR3-MAPK signaling. By activating its receptor (NPR-B) in chondrocytes, CNP inhibits the overactivated MAPK pathway, supporting more normal chondrocyte proliferation and therefore more normal bone growth. The therapeutic logic is to restore CNP-mediated inhibition of the overactive FGFR3 pathway.
Navepegritide is a CNP analog prodrug. “Prodrug” means it is administered in an inactive or slowly releasing form that is converted to active CNP in the body over time. Ascendis Pharma’s TransCon technology uses a hydrolytically cleavable linker to attach CNP to an inert carrier. After subcutaneous injection, the linker degrades slowly, releasing active CNP at a controlled, continuous rate over approximately seven days, matching the weekly dosing interval. This sustained release is the key pharmacological advance over vosoritide, which has a short half-life requiring daily injection to maintain therapeutic CNP exposure.
The APPROACH Trial: What the Evidence Shows
Trial design
The APPROACH trial (NCT05598320) was a Phase 2b, randomized, double-blind, placebo-controlled study enrolling 84 children aged 2 to 11 years with achondroplasia across seven countries. Participants were randomized 2:1 to receive navepegritide 100 μg/kg subcutaneously once weekly or placebo for 52 weeks, followed by a single-arm open-label extension (OLE) in which placebo-treated children crossed over to navepegritide.
The primary endpoint was annualized growth velocity (AGV) at week 52. Secondary endpoints included changes in skeletal proportionality measures (tibial-femoral angle, mechanical axis deviation, fibula-to-tibia length ratio) and the Achondroplasia Child Experience Measure for physical functioning.
52-week results
| Endpoint | Navepegritide | Placebo | Significance |
|---|---|---|---|
| Annualized growth velocity (AGV) | 5.84 cm/year | 3.88 cm/year | p less than 0.0001 |
| Difference in AGV (LS mean) | +1.96 cm/year | Reference | Statistically significant |
| Tibial-femoral angle | Improved | No improvement | Significant |
| Mechanical axis deviation | Improved | No improvement | Significant |
| Fibula-to-tibia length ratio | Improved | No improvement | Significant |
| Physical functioning (ACH-CPM) | Improved | No improvement | Significant |
| Safety: grade 3 or higher AEs related to drug | None reported | — | Favorable |
The nearly 2 cm/year additional AGV over placebo is the headline number. To contextualize it: untreated children with achondroplasia typically grow at rates substantially below age-matched peers without the condition. Adding nearly 2 cm/year of growth velocity, across years of treatment, could translate to several centimeters of additional stature by the end of linear growth, though height is a secondary consideration given the bone proportionality and functional improvements also observed.
The improvements in tibial-femoral angle and mechanical axis deviation are clinically significant beyond their contribution to height. These measurements reflect the degree of lower limb bowing that is common in achondroplasia and contributes to gait abnormalities, knee pain, and long-term joint health. Improving these parameters addresses functional and structural aspects of the condition, not just growth velocity.
The Achondroplasia Child Experience Measure for physical functioning is a validated patient-reported outcome instrument assessing how children experience the physical limitations of achondroplasia in daily activities. Its improvement alongside the growth and skeletal endpoints indicates that the trial captured changes meaningful to the children themselves, not only measurements observable on radiographs.
Two-year data (May 2026 update)
In May 2026, Ascendis presented two-year APPROACH trial data showing pronounced gains specifically in children aged 5 years and older. In this subgroup, navepegritide produced AGV of 5.84 cm/year (observed mean) versus 3.88 cm/year on placebo over the initial 52 weeks, with durable benefit sustained through the open-label extension. The company also presented data from the combination navepegritide plus lonapegsomatropin (once-weekly growth hormone) program, which showed mean AGV of 8.80 cm/year in treatment-naive children and exceeded the 97th-percentile AGV of average-stature children after 52 weeks, though this combination is investigational and not yet approved.
Accelerated Approval: What It Means Here
The FDA granted YUVIWEL approval under the Accelerated Approval Program, which allows approval based on a surrogate endpoint reasonably likely to predict clinical benefit. The surrogate endpoint for YUVIWEL is annualized growth velocity.
Continued approval is contingent on verification of clinical benefit in confirmatory trials. Ascendis is conducting confirmatory long-term studies evaluating final adult height and clinical functional outcomes. This is standard practice for accelerated approvals in rare pediatric diseases and does not mean the drug’s efficacy is uncertain; it means that the FDA has determined the available evidence is sufficient for approval now while longer-term confirmatory data is generated.
| YUVIWEL vs. vosoritide (Voxzogo): how they compare Vosoritide (Voxzogo, BioMarin) was the first disease-targeting drug approved for achondroplasia, in August 2021. It is a CNP analog but not a prodrug: it requires daily subcutaneous injection because its active form degrades quickly in the body. Navepegritide is a prodrug using TransCon technology to achieve weekly dosing through sustained release, providing continuous CNP exposure over the dosing interval rather than daily peaks and troughs. Both target the same CNP-FGFR3 pathway. Neither has been directly compared in a head-to-head randomized trial. The evidence for vosoritide’s efficacy comes from the pivotal ACH-003 trial, which showed a difference of 1.57 cm/year in AGV versus placebo. The APPROACH trial showed a 1.96 cm/year difference for navepegritide versus placebo. Cross-trial comparisons are unreliable and should not be used to conclude one drug is superior. The clinically relevant difference for families is dosing schedule: once-weekly versus once-daily injection. For young children, the reduction in injection frequency is a meaningful quality-of-life consideration. |
|---|
Safety Profile
The safety profile of navepegritide in the APPROACH trial was favorable, with no grade 3 or higher adverse events attributed to the drug. The most common adverse events were consistent with the expected profile of a subcutaneous injection therapy in children:
- Injection site reactions (most common, typically mild and transient)
- Headache
- Fever
- Vomiting
- Upper respiratory symptoms
No new safety signals were identified in the extended follow-up period. The full prescribing information includes complete safety data and monitoring recommendations.
Regulatory Designations
YUVIWEL received multiple FDA designations supporting its development:
- Accelerated Approval
- Rare Pediatric Disease designation (and Rare Pediatric Disease Priority Review Voucher granted alongside approval)
- Orphan Drug designation
- Breakthrough Therapy designation
As discussed in our post on the first gene therapy for genetic deafness, the Rare Pediatric Disease Priority Review Voucher is a transferable incentive granted upon approval of therapies for rare pediatric conditions. It can be used by Ascendis or sold to another pharmaceutical company to accelerate a different drug’s FDA review, and has market value in the hundreds of millions of dollars. The voucher program exists specifically to incentivize development of treatments for conditions affecting small pediatric populations where commercial markets alone would not support development costs.
What This Approval Means for Families
For a child aged 2 to 11 years with achondroplasia and open growth plates, YUVIWEL is now an FDA-approved treatment option. The practical question for most families will be a conversation with a pediatric endocrinologist or geneticist at a center specializing in skeletal dysplasia about whether navepegritide or vosoritide is the right choice for their child’s specific situation.
Key considerations include the child’s current growth trajectory, whether they are already on vosoritide, family preference for injection frequency, and access and insurance coverage. YUVIWEL is expected to be available through commercial channels beginning early Q2 2026.
For families with children being managed at a skeletal dysplasia center, this conversation should be initiated with the treating team. For families who do not have access to specialized skeletal dysplasia care, the Achondroplasia & Hypochondroplasia Alliance, Little People of America, and the National Organization for Rare Disorders (NORD) maintain physician referral resources, patient community networks, and current information on treatment options.
ClinicalTrials.gov lists ongoing navepegritide trials including the adolescent trial (NCT06732895) for ages 12 to 18 and the combination lonapegsomatropin trial, for families interested in investigational options beyond the current approval.
For related coverage of rare pediatric disease FDA approvals, see our posts on the first gene therapy for genetic deafness approved under the Rare Pediatric Disease PRV program and the UX111 gene therapy for Sanfilippo syndrome now under FDA review.
Sources
Ascendis Pharma FDA approval press release: FDA Approves Once-Weekly YUVIWEL (navepegritide) for Children with Achondroplasia Aged 2 Years and Older. GlobeNewswire. February 27, 2026.
APPROACH trial primary publication: Savarirayan R, McDonnell C, Bacino CA, et al. Once-Weekly Navepegritide in Children With Achondroplasia: The APPROACH Randomized Clinical Trial. JAMA Pediatrics. 2025;180(1):18-25. doi:10.1001/jamapediatrics.2025.4771. PMC12624480.
APPROACH trial registration (Phase 2b): NCT05598320. ClinicalTrials.gov.
Two-year APPROACH data (May 2026): New 2-Year Data from Pivotal ApproaCH Trial of TransCon CNP (Navepegritide) Show Pronounced Gains in Growth Outcomes in Children with Achondroplasia Aged 5 Years. GlobeNewswire. May 6, 2026.
Pediatric Endocrine Society clinical review: Navepegritide (Yuviwel) for Children with Achondroplasia: New Drugs and Therapeutics. pedsendo.org. March 2026.
Contemporary Pediatrics approval coverage: FDA Issues Historic Approval for Navepegritide in Achondroplasia. contemporarypediatrics.com. 2026.
Combination therapy data (HCPLive): Combination Navepegritide, Lonapegsomatropin Shows Durable Benefit in Phase 2 Pediatric Achondroplasia Trial. hcplive.com. February 2026.
Adolescent trial registration: NCT06732895. ClinicalTrials.gov.
Vosoritide FDA approval: FDA approves vosoritide for achondroplasia. FDA.gov. August 2021.
YUVIWEL prescribing information: YUVIWEL (navepegritide) full prescribing information. accessdata.fda.gov.
Achondroplasia NORD overview: Achondroplasia. NORD.
NIH GARD achondroplasia: Achondroplasia. rarediseases.info.nih.gov.
CNP biology reference: C-type natriuretic peptide and bone growth. PMC3482906.
Endochondral ossification reference: Endochondral Ossification. StatPearls. NCBI.
Accelerated Approval pathway: Accelerated Approval Program. FDA.gov.
Rare Pediatric Disease PRV: Rare Pediatric Disease Priority Review Voucher Program. FDA.gov.
Patient resources: Achondroplasia & Hypochondroplasia Alliance | Little People of America | NORD: Achondroplasia | ClinicalTrials.gov: navepegritide
| Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice. Decisions about treatment for children with achondroplasia should be made in close consultation with a pediatric endocrinologist, geneticist, or specialist in skeletal dysplasia familiar with the child’s individual growth history and clinical circumstances. |
|---|